Oncology
News
Multiparametric Magnetic Resonance Imaging Identifies Candidates for Prostate Cancer Surveillance
Major Finding: The sensitivity, specificity and overall accuracy of the NCCN guidelines were 64%, 35%, and 83% (P = .00002), compared with 93%, 54...
News
Contralateral Prophylactic Mastectomy Ups Surgical Risk
Major Finding: Unilateral breast cancer patients undergoing contralateral prophylactic mastectomy were 1.5 times more likely to experience...
News
Breast Cancer Vaccine Begins Phase III Trial
Major Finding: Disease-free survival at a median follow-up of 5 years was 95.9% in breast cancer patients who received the E75 vaccine with twice-...
News
AVEREL: Avastin Defers Progression in HER2-Positive Metastatic Breast Cancer*
Major Finding: In an assessment conducted by investigators, bevacizumab significantly improved progression-free survival when added to standard...
Conference Coverage
ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer
Major Finding: Immediate treatment with zoledronic acid reduced recurrence and mortality risk by 34% and 31%, respectively, and improved bone...
News
Medicare Study Confirms Colonoscopy's Cancer Prevention Power
Major Finding: Colonoscopy was associated with a 73% lower risk of distal colorectal cancer (hazard ratio, 0.27) and a 54% lower risk of proximal...
News
Panel Endorses Surveillance for Low-Risk Prostate Cancer
Major Finding: Many men with localized, low-risk prostate cancer should be closely monitored, permitting their treatment to be delayed until...
News
Clodronate Offered Modest Benefit for Breast Cancer Patients
Major Finding: Disease-free survival (DFS) did not differ between women treated with clodronate and those given placebo (hazard ratio, 0.91; P = ....
News
DCIS Assay Predicts Recurrence Risk After Breast Surgery
Major Finding: Twelve percent of patients with a low DCIS risk score experienced a disease recurrence within 10 years of breast-conserving surgery...
News
Dual HER2 Blockade Defers Breast Cancer Progression
Major Finding: Adding pertuzumab to a standard chemotherapy regimen of trastuzumab and docetaxel led to an additional 6 months of progression-free...
Conference Coverage
BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
Major Finding: According to updated results median progression-free survival was 7.4 months for combination therapy patients and 3.2 months for...